Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results

• Published in: Turkish journal of haematology 2019-05, Vol.36 (2), p.81-87
• Main Authors: Adıyaman, Süleyman Cem, Alacacıoğlu, İnci, Ersen Danyeli, Ayça, Türkyılmaz, Doğuş, Sevindik, Ömür Gökmen, Demirkan, Fatih, Pişkin, Özden, Özcan, Mehmet Ali, Ündar, Bülent, Özkal, Sermin, Özsan, Güner Hayri
• Format: Article
• Language: English
• ISSN: 1300-7777; 1308-5263
• DOI: 10.4274/tjh.galenos.2019.0218.0219

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). The treatment of older NHL patients has always been a struggle; however, treatment statistics have begun showing favorable results similar to those of younger DLBCL patients thanks to newer treatment protocols. Here, we analyze the progress of our own elderly DLBCL patients who were followed between 2000 and 2016 in our center. Eighty-seven DLBCL patients, who were diagnosed and treated in the Dokuz Eylül University Department of Hematology between 2000 and 2016, were included in this study. Median age was 72 (65-89) years and 13 (14.9%) patients were older than 80 years. Median follow-up time was 19 months and 45 patients (51.7%) died during the follow-up period. Median overall survival (OS) was 55 months and median progression-free survival was calculated as 27 months. Sixty-three patients (72.4%) received standard R-CHOP therapy. Complete response was seen in 46 (52.9%) patients. The median survival time for patients who had complete response was 136 months (p80 years) and younger patients (p=0.236). According to our findings, we think that being able to complete standard R-CHOP therapy is vital for the survival rate of elderly DLBCL patients.